Draft Guidance for Industry and Food and Drug Administration Staff

Commercially Distributed In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Frequently Asked Questions

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Document issued on: June 1, 2011

You should submit comments and suggestions regarding this draft document within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.regulations.gov. Identify all comments with the docket number listed in the notice of availability that publishes in the Federal Register.

For questions regarding this document contact Tonya Wilbon at 301-796-6224 (tonya.wilbon@fda.hhs.gov). For questions regarding this document as applied to devices regulated by CBER contact the Office of Communication, Outreach and Development (OCOD), 1-800-835-4709 or 301-827-1800, or email ocod@fda.hhs.gov.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Office of In Vitro Diagnostic Device Evaluation and Safety

Center for Biologic Evaluation and Research
Preface

Additional Copies

Additional copies are available from the Internet or http://www.fda.gov/cber/guidelines.htm. You may also send an e-mail request to dsmica@fda.hhs.gov to receive an electronic copy of the guidance or send a fax request to 301-847-8149 to receive a hard copy. Please use the document number 1723 to identify the guidance you are requesting.

Or, contact:

Office of Communication, Outreach and Development, HFM-40
Center for Biologics Evaluation and Research
Food and Drug Administration
1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448
Internet:
Tel: 800-835-4709 or 301-827-1800
E-mail: ocod@fda.hhs.gov
Table of Contents

I. INTRODUCTION........................................................................................................... 4

II. FDA REGULATION OF RESEARCH USE ONLY AND INVESTIGATIONAL USE ONLY IVD PRODUCTS...................................................................................... 5

III. FREQUENTLY ASKED QUESTIONS........................................................................ 7
    A. RESEARCH USE ONLY AND INVESTIGATIONAL USE ONLY IVD PRODUCTS................. 7
    B. MARKETING PRACTICES OF MANUFACTURERS WHO LABEL THEIR IVD PRODUCTS RUO AND IUO............................................................................................................. 9
I. Introduction

This draft guidance document is intended to clarify the types of in vitro diagnostic (IVD) products\(^1\) that are properly labeled “for research use only” ("RUO") or “for investigational use only” ("IUO"), and provide the responses of the Center for Devices and Radiological Health (CDRH) and the Center for Biologics Evaluation and Research (CBER) to some frequently asked questions about how such products should and should not be marketed.\(^2\)

---

1 “In vitro diagnostic products are those reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. Such products are intended for use in the collection, preparation, and examination of specimens taken from the human body. These products are devices as defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), and may also be biological products subject to section 351 of the Public Health Service Act.” Title 21, Code of Federal Regulations (CFR), section 809.3(a).

2 This guidance is only intended to apply to IVD products that have not been approved, cleared, or licensed for any use, and it is not intended to address off-label uses of any approved, cleared, or licensed products.
This document is intended for manufacturers and distributors of RUO and IUO IVD products and any other entities who label IVD products.3

RUO and IUO IVD products are distinctive in that they are devices that may themselves be used in research or investigations on human samples that may eventually lead to their clearance or approval for clinical diagnostic use,4 and they also may be marketed for and used in the research and investigation of other FDA-regulated products. Thus, the manufacturer of an IUO IVD product is not necessarily the sponsor of a clinical investigation that uses such an IVD product in a study. The manufacturer of such an IUO IVD product may legally distribute the product commercially without FDA premarket review, as long as the distribution is only for investigational use.

The marketing of unapproved and uncleared IVD products for purposes other than research or investigation (for example, for clinical diagnostic use) has led in some cases to diagnostic use of laboratory tests with unproven performance characteristics and manufacturing controls that are inadequate to ensure consistent manufacturing of the finished product. Use of such tests for clinical diagnostic purposes may mislead healthcare providers and cause serious adverse health consequences to patients, who are not aware that they are being diagnosed with research or investigational products. FDA is therefore issuing this guidance to remind manufacturers of the requirements applicable to RUO and IUO IVDs.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

### II. FDA Regulation of Research Use Only and Investigational Use Only IVD products

Section 520(g) of the Federal Food, Drug, and Cosmetic Act ("the Act"), 21 U.S.C. 360j(g), provides for the exemption of devices intended for investigational use from certain requirements of the Act if such devices comply with the procedures and conditions prescribed by that section and by regulation. For example, devices intended for investigational use that meet applicable requirements may be exempted from premarket notification and premarket approval requirements of sections 510 and 515 of the Act (21

---

3 Although Laboratory Developed Tests (LDTs) are IVD products, for the purposes of this guidance document, "in vitro diagnostic product" or "IVD product" does not include LDTs. However, manufacturers of LDTs may find this guidance helpful in determining the proper use of IVD products labeled RUO and IUO.

4 Throughout this guidance document, references to “clinical diagnostic use” and “use in clinical diagnosis” include use in making treatment decisions. The use of tests on organ or tissue donor specimens is considered to be a clinical diagnostic use when the results of the test are applied to make recipient management or transplant decisions.
U.S.C. 360, 360e, 21 U.S.C. 360j(g)(2)(A)); see also 21 CFR 812.1(a). A product’s intended use refers to the “objective intent” of those responsible for labeling the product. Intent is determined by such persons’ expressions or may be shown by the circumstances surrounding the distribution of the article.5

Device Investigations Subject to IDE Regulation
FDA’s investigational device exemption (IDE) regulation is found at 21 CFR part 812. Under 21 CFR 812.5, investigational devices must bear a label that states the following: "CAUTION--Investigational device. Limited by Federal (or United States) law to investigational use." The labeling may not represent that the device is safe or effective for the purposes for which it is being investigated. 21 CFR 812.5(b). The IDE regulation also prohibits certain practices by sponsors and investigators pertaining to the marketing and distribution of investigational devices. See 21 CFR 812.7.

Device Investigations Exempt from IDE Regulation
Investigations of diagnostic devices that meet the criteria at section 812.2(c)(3) are exempt from 21 CFR 812, with the exception of section 812.119. The criteria at section 812.2(c)(3) include compliance with section 809.10(c) and specify that testing:

- be non-invasive,
- not require an invasive sampling procedure that presents a significant risk,
- not by design or intention introduce energy into a subject, and
- not be used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure.

Labeling requirements regarding IVD products are found at 21 CFR part 809. Pursuant to 21 CFR 809.10(c), shipments and other deliveries of IVDs are exempt from the IVD labeling requirements at section 809.10(a) and (b) if either (1) there has been compliance with part 812, or (2) the investigation is not subject to part 812 and one of the following conditions is met:

(i) For a product in the laboratory research phase of development, and not represented as an effective in vitro diagnostic product, all labeling bears the statement, prominently placed: "For Research Use Only. Not for use in diagnostic procedures."

(ii) For a product being shipped or delivered for product testing prior to full commercial marketing (for example, for use on specimens derived from humans to compare the usefulness of the product with other products or procedures which are in current use or recognized as useful), all labeling bears the statement, prominently placed: "For Investigational Use Only. The performance characteristics of this product have not been established."

5 See, e.g., 21 CFR 801.4 regarding its reference to objective intent and the circumstances surrounding an article’s distribution.
For purposes of this guidance document, "labeled RUO" refers to IVD products labeled in accordance with section 809.10(c)(2)(i); "labeled IUO" refers to IVD products labeled in accordance with section 809.10(c)(2)(ii) unless otherwise specified.

Although IVD products intended solely for research use are generally exempt from most regulatory requirements, 21 CFR 807.65 does not specifically exempt foreign manufacturers who import RUO IVD products into the U.S. from establishment registration and device listing requirements. At this time, FDA intends to exercise enforcement discretion with respect to establishment registration and device listing requirements for persons who manufacture, propagate, compound, or process imported IVD products intended solely for research use. The following product codes for required importation documents reflect RUO IVD uses.

<table>
<thead>
<tr>
<th>IVD Panel</th>
<th>Product Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematology RUO IVD products</td>
<td>OTQ</td>
</tr>
<tr>
<td>Clinical Chemistry RUO IVD products</td>
<td>OTV</td>
</tr>
<tr>
<td>Clinical Toxicology RUO IVD products</td>
<td>OTW</td>
</tr>
<tr>
<td>Pathology RUO IVD products</td>
<td>OTU</td>
</tr>
<tr>
<td>Microbiology RUO IVD products</td>
<td>OTT</td>
</tr>
<tr>
<td>Immunology RUO IVD products</td>
<td>OTR</td>
</tr>
</tbody>
</table>

Manufacturers of devices regulated by CBER should contact CBER to discuss product identifiers for RUO IVDs for use on required importation documents.

### III. Frequently Asked Questions

#### A. Research Use Only and Investigational Use Only IVD products

1. **What types of products does FDA generally consider to be appropriately labeled "Research Use Only" IVD products?**

As explained above, 21 CFR 809.10(c)(2)(i) exempts IVD products intended only for research use from the IVD labeling requirements at section 809.10(a) and (b) if the product is in the laboratory research phase of development, is not represented as an effective in vitro diagnostic product, and is labeled: “For research use only. Not for use in diagnostic procedures.”

During the laboratory research phase of development, the focus of manufacturer-initiated studies is typically to evaluate design, limited-scale performance, and issues such as usability of the test. Some examples of products FDA would consider to be in this research phase include:

- Tests that are in development to identify test kit methodology, necessary...
components, and analytes to be measured;

- Instrumentation or other electrical/mechanical components under development to determine correct settings, subcomponents, subassemblies, basic operational characteristics, and possible use methods;
- Reagents under development to determine production methods, purification levels, packaging needs, shelf and storage life, etc.

FDA also recognizes within the category of RUO IVD products certain products intended for use in non-clinical laboratory research with goals other than the development of a commercial IVD product. These include products intended for use in discovering and developing novel and fundamental medical knowledge related to human disease and conditions. For example, instruments and reagents intended for use in research attempting to isolate a gene linked with a particular disease may be labeled RUO when such instruments and reagents are not intended to produce results for clinical use.

With respect to both categories of RUO IVD products, the required labeling is meant to serve as a warning that products so labeled should not be used in clinical diagnosis or patient management.

2. **What types of IVD products should not be labeled RUO?**

Any IVD product that is intended for use in a clinical investigation or clinical diagnostic use outside an investigation (for example, in clinical diagnosis) should not be labeled RUO. FDA would consider such an IVD product to be misbranded under section 502(a) of the Act, 21 U.S.C. 352(a), if it were labeled RUO or otherwise labeled for research use.

3. **What types of products does FDA generally consider to be appropriately labeled "Investigational Use Only" IVD products?**

Investigational IVD products are those that are the subject of an investigation. 21 CFR 812.3(g). As explained above, investigational IVD products may or may not be subject to most provisions of 21 CFR 812. Investigational IVD products that do not meet the exemption criteria of section 812.2(c)(3) must comply with part 812, including the requirement that they bear a label with the statement: "CAUTION--Investigational device. Limited by Federal law to investigational use." 21 CFR 812.5.

In order to be exempt from 21 CFR 812, an investigation of an IVD product must meet the criteria of section 812.2(c)(3) (see above), including that it not be used as a diagnostic procedure without confirmation of the diagnosis by another, medically-established diagnostic product or procedure. If the investigation meets these criteria, a product being shipped or delivered for product testing prior to full commercial marketing is exempt from the IVD labeling requirements at section 809.10(a) and (b) as long as it is labeled: "For Investigational Use Only. The performance characteristics of this product have not been established.” 21 CFR 809.10(c)(2)(ii). For example, IVD products
under investigation that FDA would consider to fall in this category include those that are being evaluated in comparison studies that use archived or fresh specimens to determine performance characteristics.

4. What types of IVD products should not be labeled IUO?

Any IVD product that is intended for non-investigational purposes, such as in clinical diagnostic use outside of an investigation, should not be labeled IUO. FDA would consider such an IVD product to be misbranded under section 502(a) of the Act, 21 U.S.C. 352(a), if it is labeled with the statement: "For Investigational Use Only" or “Investigational device.”

Investigational IVD products subject to 21 CFR 812 must be labeled in accordance with section 812.5 and should not be labeled in accordance with section 809.10(c)(2)(ii). Investigational IVD products exempt from part 812 under section 812.2(c)(3) must be labeled in accordance with section 809.10(c)(2)(ii) and should not be labeled in accordance with section 812.5.

5. Are RUO and IUO IVD products required to be manufactured in compliance with the Quality System regulation?

FDA does not require RUO IVD products or IUO IVD products that meet the conditions for exemption from 21 CFR 812 to be manufactured in compliance with the Quality System (QS) regulation (21 CFR 820). Investigational use IVD products that are not exempt from 21 CFR 812 and that comply with part 812 are exempt from QS requirements except for those found in 21 CFR 820.30 (design controls), if applicable. 21 CFR 812.1(a). Thus, investigational use IVD products that are not exempt from part 812 should not be shipped to sites for investigational use until required design control activities have been completed and documented, as required by section 820.30, if applicable.

B. Marketing Practices of Manufacturers who Label their IVD Products RUO and IUO

1. How may IVD products labeled RUO or IUO be marketed?

As explained above, RUO and IUO IVD products may be studied for clearance or approval, but they also may be marketed for and used in the research and investigation of other products. Thus, a manufacturer who labels its IVD product RUO may promote and market it for research use, for example, by general discovery laboratories. By the same token, a manufacturer who labels its IVD product IUO may promote and market it for use in a clinical investigation that is exempt from 21 CFR 812.
2. What marketing practices would FDA consider to be generally inappropriate for IVD products labeled RUO or IUO?

The mere placement of an RUO or IUO label on an IVD product does not render the device exempt from clearance, approval, or other requirements, regardless of how it is marketed. Whether it bears an RUO or IUO label, or neither, an IVD product that is not intended for research or investigational purposes would not qualify for the applicable exemptions at section 520(g) of the Act, 21 U.S.C. 360j(g) (see section II above). If such an IVD product were not cleared or approved, FDA would consider it to be adulterated under section 501(f) of the Act, 21 U.S.C. 351(f), and misbranded under section 502(o) of the Act, 21 U.S.C. 352(o), unless exempt from premarket notification requirements. As explained above, FDA would also consider an IVD product that is labeled RUO but not intended for research or labeled IUO but not intended for investigational purposes to be misbranded under section 502(a) of the Act, 21 U.S.C. 352(a).

In addition to overt expressions by the manufacturer such as those present in labeling and advertising, intended use may be shown by the circumstances surrounding the distribution of the product and the manufacturer’s knowledge that its product is offered and used for a purpose for which it is neither labeled nor advertised. For example, FDA may consider a manufacturer’s knowledge of the purposes for which its customers offer and use its IVD product, and the manufacturer’s provision of technical support for those activities, to be evidence that the IVD product is intended to be used for such purposes. The weight of this evidence will vary with the circumstances.

FDA will assess the following marketing practices as evidence of an intended use that conflicts with RUO labeling, and thus generally inappropriate for IVD products labeled RUO:

- Written or verbal statements in any labeling, advertising, or promotion of the IVD product, including any performance claims, clinical information, product names, or descriptors, that claim or suggest that the IVD product may be used in a clinical investigation or for any clinical diagnostic use;

- Written or verbal statements in any labeling, advertising, or promotion of the IVD product that suggest that clinical laboratories can validate the test through their own investigational procedures and subsequently offer it for clinical diagnostic use as a laboratory developed test;

- Sales to clinical laboratories that the manufacturer knows, or has reason to know, use the IVD product in clinical diagnostic use in an investigation or otherwise, and support (including technical support) for those activities.

- Past history of promotion of the product

---

6 See, e.g., 21 CFR 801.4.
FDA will assess the following marketing practices as evidence of an intended use that conflicts with IUO labeling, and is thus generally inappropriate for IVD products labeled IUO:

- Written or verbal statements in any labeling, advertising, or promotion of the IVD product that claim or suggest that the IVD product may be used in non-investigational clinical diagnostic use;
- Written or verbal statements in any labeling, advertising, or promotion of the IVD product that claim or suggest that the IVD product may be used in a manner that is inconsistent with an exempt investigation (see 21 CFR 812.2(c));
- Sales to clinical laboratories that the manufacturer knows, or has reason to know, use the IVD product in non-investigational clinical diagnostic use or in an investigation that is not exempt from 21 CFR part 812 and support (including technical support) for those activities.
- Past history of promotion of the product

3. **What should a manufacturer do if it learns that one of its clinical laboratory customers wants to use an IVD product labeled RUO or IUO in clinical diagnosis?**

FDA is aware that laboratories sometimes use IVD products labeled RUO in clinical diagnosis and that many manufacturers, importers, and distributors of IVD products labeled RUO are also aware of such use. Manufacturers who label their IVD products: “For Research Use Only. Not for use in diagnostic procedures,” should not sell such products to laboratories that they know use the product for clinical diagnostic use. If a manufacturer learns that a laboratory to which it sells its RUO-labeled IVD product is using it in clinical diagnosis, it should halt such sales or comply with FDA requirements for IVD products, including premarket review requirements, if applicable. FDA fully supports the use of IVD products labeled RUO for research purposes, but since these products may not be manufactured in accordance with current Good Manufacturing Practice (cGMP) and their performance characteristics have not been established, we believe they present a serious potential risk to the public health when used in clinical laboratories to generate tests results intended for patient management.

---

7 For purposes of this guidance, clinical laboratories include blood establishments as defined in 21 CFR 607.3(c) (“Establishment means a place of business under one management at one general physical location. The term includes, among others, human blood and plasma donor centers, blood banks, transfusion services, other blood product manufacturers and independent laboratories that engage in quality control and testing for registered blood product establishments.”) and establishments as defined in 21 CFR 1271.3(b) (“Establishment means a place of business under one management, at one general physical location, that engages in the manufacture of human cells, tissues, and cellular and tissue-based products.”).
Manufacturers who label their IVD products IUO should not sell them to laboratories that they know use the product for clinical diagnostic use outside of a clinical investigation. If a manufacturer learns that a clinical laboratory to which it sells its IUO-labeled IVD product is using these IUO-labeled IVDs for non-investigational diagnostic use, it should halt sales for such use or comply with FDA regulations for IVD products, including premarket review requirements, if applicable.

4. **Can a manufacturer obtain clearance or approval for an IVD product that includes or is required to be used with one or more IUO and/or RUO-labeled reagents or instruments?**

A manufacturer that is planning to submit a premarket notification (510(k)), an application for premarket approval (PMA), or a biologics license application (BLA) for a test that uses an RUO or IUO-labeled reagent or instrument should include data regarding the RUO or IUO product as part of their submission. Once the IVD product is cleared or approved, the RUO or IUO-labeled reagent and/or instrument should be relabeled to indicate that it is cleared or approved for use with that specific IVD product.

5. **Should a manufacturer or distributor promote IVD components, instruments, or reagents labeled RUO or IUO for use in an LDT that the manufacturer knows is used in clinical diagnosis?**

No. Labeling an IVD component, instrument, or reagent RUO or IUO is not consistent with their use in an LDT used in clinical diagnosis. FDA would consider promotion of IVD components, instruments, or reagents labeled RUO or IUO for use in an LDT that the manufacturer knows is used to provide clinical results outside an investigation to be evidence of an intended use that conflicts with RUO and IUO labeling, which may render the device misbranded under section 502(a) of the Act, 21 U.S.C. 352(a). As explained in section III.B.2. above, unless exempt from premarket notification requirements, if such an IVD product were not cleared or approved, it may also be rendered adulterated under section 501(f) of the Act, 21 U.S.C. 351(f) and misbranded under section 502(o) of the Act, 21 U.S.C. 352(o).

6. **Should the manufacturer include instructions for use with an IVD product labeled RUO or IUO?**

In certain circumstances, such as when the use of an IVD product labeled RUO is limited to laboratory research that is unrelated to the development of IVDs (see discussion in section III.A.1. above), general instructions for using the product (for example, mixing proportions, incubation times, etc.) may be provided. However, no clinical interpretive information, discussion of clinical significance, or other indications of clinical applicability should be included with any IVD products labeled RUO, as this would suggest that they may be used for non-research purposes, which would conflict with their RUO labeling. For those products that are in the research phase of IVD development,
there is unlikely to be a need for instructions for use, as such products are still in their
formative stages.

For IVD products labeled IUO that are the subject of a clinical investigation by a sponsor
other than the manufacturer, it is acceptable to provide instructions for use to the sponsor
of the study using the format described in 21 CFR 809.10(b).

7. Is it appropriate for a manufacturer or distributor to market software labeled
RUO or IUO?

Yes, software that is a stand-alone IVD product, or a component of or an accessory to
another IVD product, which is labeled in accordance with 21 CFR 809.10(c)(2), may be
marketed for research or investigational use to entities conducting research or
investigations with the software. Such software is subject to the same limitations on
promotion and marketing as other IVD products labeled RUO or IUO.

8. Should the manufacturer of an IVD product labeled RUO or IUO help with the
validation and verification of performance specifications of an LDT or other test
that the manufacturer knows is used in clinical diagnosis that utilizes its
product?

No. If the manufacturer of an IVD product labeled RUO were to assist in the validation
or verification of the performance of a test that the manufacturer knows is used in clinical
diagnosis using its RUO-labeled IVD product, FDA would consider such assistance to be
evidence of non-research intended use. As explained above, this may render the device
misbranded under sections 502(a) and 502(o) of the Act, 21 U.S.C. 352(a), 352(o), and
adulterated under section 501(f) of the Act, 21 U.S.C. 351(f).

If the manufacturer of an IVD product labeled IUO were to assist in the validation or
verification of the performance of a test that the manufacturer knows is used in
non-investigational clinical diagnosis using its IUO-labeled IVD, FDA would consider
such assistance to be evidence of non-investigational intended use. As explained above,
this may render the device misbranded under sections 502(a) and 502(o) of the Act, 21
U.S.C. 352(a), 352(o), and adulterated under section 501(f) of the Act, 21 U.S.C. 351(f).